Erika Richtig

8PUBLICATIONS
47CO-AUTHORS
Predictive and prognostic markersInnate immunityBiological network analysisTumour immunologyEpidemiological modelling
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 20, 2024
Late stage melanoma is hallmarked by low NLGN4X expression leading to HIF1A accumulation.

David Schörghofer, Laurenz Vock, Madalina A Mirea

|Jul 14, 2023
Assessing the Performance of a Novel Stool-Based Microbiome Test That Predicts Response to First Line Immune Checkpoint Inhibitors in Multiple Cancer Types.

Irina Robinson, Maximilian Johannes Hochmair, Manuela Schmidinger

|Jul 07, 2023
Predatory journals: Perception, impact and use of Beall's list by the scientific community-A bibliometric big data study.

Georg Richtig, Marina Berger, Max Koeller

|Jun 12, 2023
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.

Reinhard Dummer, Pippa Corrie, Ralf Gutzmer

|Dec 29, 2022
Suction Drain Volume following Axillary Lymph Node Dissection for Melanoma-When to Remove Drains? A Retrospective Cohort Study.

Raimund Winter, Alexandru Tuca, Paul Wurzer

|Sep 01, 2022
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial.

Paolo A Ascierto, Mario Mandalà, Pier Francesso Ferrucci

Pageof 2

Frequent Collaborators

2 joint publications

Reinhard Dummer

2 joint publications

Paolo A Ascierto

2 joint publications

Celeste Lebbè

2 joint publications

Pier Francesso Ferrucci